Akerman Receives 'Litigation Department of the Year' Award for Second Consecutive Year
GlobeNewswire - Fri Apr 18, 10:15AM CDT
Akerman LLP, a top 100 U.S. law firm serving clients across the Americas, today announced that the Daily Business Review has named Akerman winner of its "Litigation Departments of the Year" award for the second consecutive year. The firm was awarded in the general litigation category for its work as a large law firm, as well as in intellectual property category for its extraordinary success in the field.
Insider Trading Alert - OPK, PSMT And LTM Traded By Insiders
at The Street - Thu Apr 17, 10:30AM CDT
Stocks with insider trader activity include OPK, PSMT and LTM
OPKO Acquires Next Generation Dry Powder Inhaler to Treat Respiratory Disorders
Business Wire - Thu Apr 17, 10:22AM CDT
OPKO Health, Inc. (NYSE:OPK) has entered into a definitive agreement to acquire Inspiro Medical Ltd. ("Inspiro"
The Global Market for Biomarkers: Concise Analysis of the $25 Billion Industry
M2 - Tue Apr 15, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r7r264/the_global_market) has announced the addition of the "The Global Market for Biomarkers: Cancer Markers, Cardiac Markers, Blood Markers, Endocrine Markers, Infectious Disease and Neurological Disease Markers" report to their offering. The global medical biomarker market is valued at about $25.9 billion for 2013, an increase of 10.2% since last year. Many biomarkers are now successfully marketed with several of them part of a routine diagnostic and treatment plan, with new products in the pipeline. Biomarkers are anatomic, physiologic, genetic, biochemical or molecular parameters. Biomarkers are detectable and measureable by a variety of methods including laboratory assays and medical imaging. Each biomarker is characteristic as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. An example is creatine kinase, or CK-MB, a marker that facilitates high-energy phosphates in the body's tissues, and can suggest a cardiovascular event when levels are high. The cancer biomarker, or tumor marker, market is one of the more advanced segments with viable products, and currently the largest segment, according to the report. The report says the majority of competitive participation for medical biomarkers is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. There are numerous companies in the market, including multiproduct companies such as Abbott and Roche, as well as small niche developers, such as 20/20 GeneSystems, CardioDx or MemoryDx. Key Topics Covered: Chapter One: Executive Summary Chapter Two: Introduction To The Medical Biomarkers Industry Chapter Three: Industry Trends Chapter Four: Biomarkers In Cancer Chapter Five: Biomarkers In Cardiovascular Disease And Blood Disorders Chapter Six: Biomarkers In Endocrine And Immune Disorders Chapter Seven: Biomarkers In Infectious Disease Chapter Eight: Biomarkers In Nervous System Disorders Chapter Nine: Market Summary Chapter Ten: Company Profiles - 20/20 GeneSystems - Abbott Laboratories - Affymetrix - Agendia - Alere - Beckman Coulter - Becton Dickinson - Biocartis SA - Biodesix - bioMerieux - BioReference Laboratory - bioTheranostics - CardioDX - Celera Alameda - Clarient - deCODE Genetics - DiaGenic - Genomic Health - Johnson & Johnson - Life Techologies - Memory Dx - Myriad Genetics - Nanostring Technologies - OPKO Health - Provista Dx - Qiagen - Roche - Seimens Healthcare - Tethys Bioscience - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/r7...bal_market
Opko Health Set to Possibly Rebound After Yesterday's Selloff of 5.64%
Comtex SmarTrend(R) - Mon Apr 14, 5:44PM CDT
Opko Health (NYSE:OPK) traded in a range yesterday that spanned from a low of $8.11 to a high of $8.98. Yesterday, the shares fell 5.6%, which took the trading range below the 3-day low of $8.72 on volume of 4.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Insider Trading Alert - ROST, OPK And AMBA Traded By Insiders
at The Street - Mon Apr 14, 10:45AM CDT
Stocks with insider trader activity include ROST, OPK and AMBA
6.4% Return Seen to Date on SmarTrend Opko Health Call (OPK)
Comtex SmarTrend(R) - Thu Apr 10, 11:27AM CDT
SmarTrend identified an Uptrend for Opko Health (NYSE:OPK) on February 14th, 2014 at $8.77. In approximately 2 months, Opko Health has returned 6.45% as of today's recent price of $9.33.
5 Stocks Insiders Love Right Now
at The Street - Wed Apr 09, 12:31PM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
CEO of Opko Health, Inc. (OPK)-NY bought Shares of OPK
M2 - Wed Apr 09, 11:04AM CDT
Reported by InsiderCow.com at 2014-04-08 08:00:02 ET
Insider Trading Alert - OPK, LVLT And LRCX Traded By Insiders
at The Street - Mon Apr 07, 9:45AM CDT
Stocks with insider trader activity include OPK, LVLT and LRCX
OPKO Health Announces Key Executive Appointments for Renal Division
Business Wire - Thu Apr 03, 11:33AM CDT
--Stephen A. Strugnell Joins as Senior Director, Scientific Affairs
Morning Movers in Biotech: Medicines Co., Omeros Corporation, Opko Health, Inc. and VIVUS, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Apr 03, 8:03AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for The Medicines Company , Omeros Corp. , Opko Health and VIVUS, . FDA accepts The Medicines Company's Biologic License Application for Fibrocaps ...
Insider Trading Alert - SEIC, OPK And DCI Traded By Insiders
at The Street - Tue Apr 01, 9:30AM CDT
Stocks with insider trader activity include SEIC, OPK and DCI
OPKO Health Announces Executive Appointments
Business Wire - Tue Apr 01, 8:25AM CDT
--Arie Gutman Appointed Chief Executive Officer of OPKO's Active Pharmaceutical Ingredient and Chemical Development Division
OPKO Announces Launch of 4Kscore Test for Prostate Cancer
Business Wire - Mon Mar 31, 10:29AM CDT
OPKO Health, Inc. (NYSE:OPK) announced the availability of the 4Kscore(TM) Test through its CLIA-accredited OPKO Lab in Nashville, TN. The laboratory-developed test is designed to enhance the prostate biopsy decision making process that, in the United States, leads to approximately 1 million biopsies being performed annually, with 80% of the results indicating no cancer or a low-grade cancer. The 4Kscore(TM) Test will help to reduce unnecessary prostate biopsies by providing information on the risk (probability) of having high-grade prostate cancer.
Why 2014 May Be a Big Year for Opko Health, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 9:27PM CDT
Philip Frost has never been shy about backing his investments. Frost, the former founder of IVAX , and Chairman of generic heavyweight Teva Pharmaceuticals , has big stakes in a variety of emerging health-care companies. However, out of all his...
Biotech Equities Technical Study -- Research on Prana Biotechnology, Amarin, United Therapeutic, and OPKO Health
PR Newswire - Fri Mar 28, 11:19AM CDT
On Thursday, March 27, 2014, the NASDAQ Composite ended at 4,151.23, down 0.54%, the Dow Jones Industrial Average edged 0.03% lower to 16,264.23, and the S&P 500 closed at 1,849.04, down 0.19%. The losses were broad based with seven out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 671.20, down 0.13%, and the index has fallen by 2.20% in last one month. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR) and OPKO Health Inc. (NYSE: OPK). Free technical research on PRAN, AMRN, UTHR and OPK can be downloaded upon signing up at:
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 26, 4:20PM CDT
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
American Urological Association (AUA) Accepts 4Kscore Test Clinical Study for Plenary Presentation at 2014 Annual Meeting
Business Wire - Tue Mar 25, 11:18AM CDT
OPKO Health, Inc. (NYSE:OPK) today announced that the American Urological Association (AUA) has accepted "The 4Kscore(TM) Test as a Predictor of High-Grade Prostate Cancer on Biopsy" as a Late-Breaking Abstract for presentation in Plenary I on Sunday May 18, 2014 at the AUA Annual meeting in Orlando, FL.
Insider Trading Alert - OPK, WDAY And CHD Traded By Insiders
at The Street - Tue Mar 25, 9:30AM CDT
Stocks with insider trader activity include OPK, WDAY and CHD